A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia
about
Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models.A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor ModelNeuronal migration abnormalities and its possible implications for schizophreniaFunctional regulation of GABAA receptors in nervous system pathologiesThe role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophreniaNegative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotionDrug models of schizophreniaPotential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases.Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model.Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia.GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.Corticolimbic hyper-response to emotion and glutamatergic function in people with high schizotypy: a multimodal fMRI-MRS studyHippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophreniaVagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophreniaAlterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophreniaSchizophrenia: an integrated sociodevelopmental-cognitive model.Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia modelNegative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.GABA(A) receptor α subunits differentially contribute to diazepam tolerance after chronic treatment.Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticityEster to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit.Gestational methylazoxymethanol acetate administration alters proteomic and metabolomic markers of hippocampal glutamatergic transmission.Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia.Tonic Inhibitory Control of Dentate Gyrus Granule Cells by α5-Containing GABAA Receptors Reduces Memory InterferenceSelective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysisImpaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.The MAM rodent model of schizophreniaα5GABAA receptor deficiency causes autism-like behaviorsPeripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.The Nucleus Reuniens of the Midline Thalamus Gates Prefrontal-Hippocampal Modulation of Ventral Tegmental Area Dopamine Neuron Activity.Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging studySchizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophreniaDisinhibition, an emerging pharmacology of learning and memorySh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects.Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.Leading compounds for the validation of animal models of psychopathology.
P2860
Q21129461-D1A0C198-91AB-4141-848D-888C3CD2FDEFQ26774869-A8478666-C13C-4440-A3A8-C37B5AA2DEF4Q26824953-C686CD5F-C88A-4CB3-9F43-F0F65C267EE8Q27013597-2BF8FA53-06F4-438E-A4FD-C5600A748B57Q27026637-261F568A-AAB4-423F-819A-FFEFC55EF1ABQ27325106-74D06A71-1997-404B-A8F8-D953C94597FCQ28084198-5DA8AA78-7978-411B-8FF0-358664B61FECQ30357529-FDECFB94-72B1-4076-BEE5-17E9DE2D2970Q30405706-997384D4-1BB9-4947-88E5-B4CE315DFDBAQ30412701-33744DBA-CA25-477B-82A4-C2C388C19CC0Q30421260-E8D3A5A2-ECBA-4D60-BD6A-7464294A873FQ30466591-6D662911-B89E-4DF0-AA26-C8B237FD91E0Q30540732-B60B9A92-5AC5-45F1-974E-383677AE3DD7Q33635658-B4ED9AC7-861B-4222-95B1-46B208DEE773Q33637819-6CB1AD7F-59A2-4447-9596-E637D422A178Q33865310-983E7095-AD9A-4132-A873-DFFDA4DD4EBCQ33932787-7C5FFF7B-CD3E-4258-B34D-8963D4FFF6FBQ34023115-A51DBE87-D34F-478B-974F-2D136FD0F50FQ34167594-D4D720ED-4F7B-42AF-931E-51299278500AQ34236634-7BFB4782-6DE8-4D87-BE03-3AA58160F82BQ34389218-38FF6BAF-2F57-4450-96FC-2FA06B133BCBQ34466181-951415E7-C302-457D-B7FE-FE1861A53E81Q34540561-3CC4C58E-8E56-4076-B115-99FE4B5D9A4FQ35622696-70616F76-FD2B-4617-A66B-5B86D55B5DF6Q35915861-F505AEA8-C4E7-4B15-945A-1A1FB2F4EBE3Q36128349-90145789-DB3C-4C71-89E3-2BF824E9DAA7Q36243393-19FE2394-95D0-4B8C-A310-2B72C56E2920Q36393853-2E4E8FCF-04EC-4C2B-BE45-18A216F70581Q36604589-681EFA2A-349B-4587-B55F-8296631E3D00Q36849520-7EE5C922-3359-426E-8EE7-500D740289B3Q36891740-E49FE998-BCF4-4172-A976-E96FF20986B7Q37103318-5700F80B-8D91-426B-ADB9-015D5DC24EB4Q37198435-EBEF818B-ADD8-4838-B13A-4FD8B5ADF621Q37256211-B99CCD14-9A06-4CFF-B6A1-A91B9BE6D492Q37458220-80378E77-5117-464A-8787-A8238B8069B2Q37598278-D2A69151-CFEC-4F7E-971F-30235AEB7718Q37635772-4960E9E0-DDB1-4C5D-B071-376DC6E6296CQ37718608-3236BAFD-A56B-4AA1-BE47-48D846B48D39Q37881426-A6658FE6-110F-419A-9A88-1065B4FB8229Q38128733-C7EFB225-D2AD-42D2-9625-4F36C306405F
P2860
A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@ast
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@en
type
label
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@ast
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@en
prefLabel
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@ast
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@en
P2093
P2860
P356
P1476
A novel α5GABA(A)R-positive al ...... the MAM model of schizophrenia
@en
P2093
Daniel J Lodge
James M Cook
Kathryn M Gill
Shamim Aras
P2860
P2888
P304
P356
10.1038/NPP.2011.76
P407
P577
2011-05-11T00:00:00Z